Last reviewed · How we verify
Vigabatrin Tablets
At a glance
| Generic name | Vigabatrin Tablets |
|---|---|
| Also known as | Sabril |
| Sponsor | Kullasate Sakpichaisakul |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Inhibiting GABA Transaminase to Relieve Obesity Induced Hyperinsulinemia and Insulin Resistance (PHASE2)
- Vigabatrin With High Dose Prednisolone Combination Therapy vs Vigabatrin Alone for Infantile Spasm (NA)
- Safety and Efficacy Study of Vigabatrin to Treat Methamphetamine Dependence (PHASE2)
- Bioequivalence Study of Vigabatrin ORPHELIA Pharma 500mg Soluble Tablets and SabrilTM 500mg Granules for Oral Administration (PHASE1)
- Acceptability Study of a New Paediatric Form of Vigabatrin in Infants and Children With Infantile Spasms or Pharmacoresistant Partial Epilepsy (NA)
- Proof-of-Concept Safety Study of CPP-109 (Vigabatrin) for Treatment Refractory Tourette's Disorder (PHASE1, PHASE2)
- A Study of the Structure and Function of the Retina in Adult Patients With Refractory Complex Partial Seizures Treated With Vigabatrin (Sabril®) (PHASE4)
- Vigabatrin for the Treatment of Cocaine Dependency (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |